Clinical and microbiological features of ceftolozane/tazobactam-resistant Pseudomonas aeruginosa isolates in a university hospital in central Italy. (September 2022)
- Record Type:
- Journal Article
- Title:
- Clinical and microbiological features of ceftolozane/tazobactam-resistant Pseudomonas aeruginosa isolates in a university hospital in central Italy. (September 2022)
- Main Title:
- Clinical and microbiological features of ceftolozane/tazobactam-resistant Pseudomonas aeruginosa isolates in a university hospital in central Italy
- Authors:
- Morroni, Gianluca
Brescini, Lucia
Antonelli, Alberto
Di Pilato, Vincenzo
Castelletti, Sefora
Brenciani, Andrea
D'Achille, Gloria
Mingoia, Marina
Giovanetti, Eleonora
Fioriti, Simona
Masucci, Annamaria
Giani, Tommaso
Giacometti, Andrea
Rossolini, Gian Maria
Cirioni, Oscar - Abstract:
- Highlights: Ceftolozane/tazobactam (C/T) is a new cephalosporin β-lactamase inhibitor combination. Pseudomonas aeruginosa harbored various resistance mechanisms to C/T. Metallo β-lactamase and extended spectrum β-lactamase (ESBL) are the main resistance mechanisms. Epidemiology and resistance mechanisms to C/T varied in P. aeruginosa strains. ABSTRACT: Objectives: Ceftolozane/tazobactam (C/T) is a novel cephalosporin and β-lactamase inhibitor combination with great activity against Pseudomonas aeruginosa . To assess P. aeruginosa susceptibility to C/T, a surveillance study was conducted from October 2018 to March 2019 at the University Hospital 'Ospedali Riuniti' in Ancona, Italy. Methods: Minimum inhibitory concentrations (MICs) to C/T were determined by Etest strip. Resistant isolates were characterized by phenotypic (broth microdilution antimicrobial susceptibility testing and modified Carbapenem Inactivation Method [mCIM]) and genotypic (Polymerase Chain Reaction [PCR], Pulsed Field Gel Electrophoresis [PFGE], and whole-genome sequencing [WGS]) methods. Clinical variables of patients infected by C/T-resistant P. aeruginosa were collected from medical records. Results: Fifteen of 317 P. aeruginosa collected showed resistance to C/T (4.7%). Ten strains demonstrated carbapenemase activity by mCIM method, and PCR confirmed that eight strains harbored a blaVIM gene while the other two were positive for blaIMP . Additionally, three isolates carried acquired extended spectrumHighlights: Ceftolozane/tazobactam (C/T) is a new cephalosporin β-lactamase inhibitor combination. Pseudomonas aeruginosa harbored various resistance mechanisms to C/T. Metallo β-lactamase and extended spectrum β-lactamase (ESBL) are the main resistance mechanisms. Epidemiology and resistance mechanisms to C/T varied in P. aeruginosa strains. ABSTRACT: Objectives: Ceftolozane/tazobactam (C/T) is a novel cephalosporin and β-lactamase inhibitor combination with great activity against Pseudomonas aeruginosa . To assess P. aeruginosa susceptibility to C/T, a surveillance study was conducted from October 2018 to March 2019 at the University Hospital 'Ospedali Riuniti' in Ancona, Italy. Methods: Minimum inhibitory concentrations (MICs) to C/T were determined by Etest strip. Resistant isolates were characterized by phenotypic (broth microdilution antimicrobial susceptibility testing and modified Carbapenem Inactivation Method [mCIM]) and genotypic (Polymerase Chain Reaction [PCR], Pulsed Field Gel Electrophoresis [PFGE], and whole-genome sequencing [WGS]) methods. Clinical variables of patients infected by C/T-resistant P. aeruginosa were collected from medical records. Results: Fifteen of 317 P. aeruginosa collected showed resistance to C/T (4.7%). Ten strains demonstrated carbapenemase activity by mCIM method, and PCR confirmed that eight strains harbored a blaVIM gene while the other two were positive for blaIMP . Additionally, three isolates carried acquired extended spectrum β-lactamase genes (two isolates carried blaPER and one carried blaGES ). Eight strains were strictly related by PFGE and WGS analysis confirmed that they belonged to sequence type (ST)111. The other STs found were ST175 (two isolates), ST235 (two isolates), ST70 (one isolate), ST621 (one isolate), and the new ST3354 (one isolate). Most patients had received previous antibiotic therapies, carried invasive devices, and experienced prolonged hospitalization. Conclusion: This study demonstrated the presence of C/T-resistant P. aeruginosa isolates in a regional hospital carrying a number of resistance mechanisms acquired by different high-risk clones. … (more)
- Is Part Of:
- Journal of global antimicrobial resistance. Volume 30(2022)
- Journal:
- Journal of global antimicrobial resistance
- Issue:
- Volume 30(2022)
- Issue Display:
- Volume 30, Issue 2022 (2022)
- Year:
- 2022
- Volume:
- 30
- Issue:
- 2022
- Issue Sort Value:
- 2022-0030-2022-0000
- Page Start:
- 377
- Page End:
- 383
- Publication Date:
- 2022-09
- Subjects:
- Ceftolozane/tazobactam -- Pseudomonas aeruginosa -- β-lactamase
Drug resistance -- Periodicals
Drug resistance -- Periodicals
Drug resistance
Periodicals
616.9041 - Journal URLs:
- http://www.sciencedirect.com/science/journal/22137165 ↗
http://www.sciencedirect.com/ ↗
http://www.bibliothek.uni-regensburg.de/ezeit/?2710046 ↗
http://www.elsevier.com/locate/jgar ↗ - DOI:
- 10.1016/j.jgar.2022.07.010 ↗
- Languages:
- English
- ISSNs:
- 2213-7165
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 23327.xml